Using alternative cell types, such as yeast, could reduce mAb production time from 5-6 months to 2-3 months. MIT studied the readiness of a yeast currently used to produce commercial therapeutic monoclonal antibody for rapid responses to pandemic situations.
Steps of the project included:
Established reference cells and materials to guide additional development for fast efficient production of Mabs in a yeast organism that could enhance capabilities for pandemic responses.
Informed an alternative manufacturing solutions for on-going responses to protect from COVID-19 or other emerging pathogens.
Directly advanced the biotechnologies that enable small‐footprint biomanufacturing of proteins.
Proof-of-concept data from this study for sustained continuous production of recombinant protein using yeast provides support for next‐generation manufacturing strategies for fast, efficient production of recombinant proteins that may enable improved equitable access and affordability of medicines in the United States and globally, including mAbs and other recombinant protein products such as insulin.
This project demonstrated an alternative yeast expression workflow that accelerates cell‑line creation and mAb readiness for drug companies, resulting in time benefits across non‑CHO mAb expression platforms.
A common point of reference for mAbsproduced in an alternative yeast host that can be used to establish additional engineeringdirections on strains for further improvements
Create baseline strains producing the NIST mAb for other potential efforts in process equipment and process implementation developments.
Additional benefit for advancing innovation of manufacturing with yeast is the potential for improving equitable access and affordability of medicines, including mAbs and other recombinant protein products like insulin.
Love, C., Presenter, ARP-28 Monoclonal antibody expression in fast alternative hosts: Demonstration & Reference Material, NIIMBL National Meeting, Washington, D.C., July 28, 2022.
Love, C., Dalvie, C., Johnston, J., ARP-28 Monoclonal Antibody Expression in Fast Alternative Hosts, NIIMBL National Meeting. Washington, D.C., July 26-28, 2022.
Love, C., Presenter, Monoclonal Antibody Expression in Fast Alternative Hosts: Demonstration & Reference Material (ARP-28), NIIMBL Member Forum, Virtual, December 1, 2022.
Login to the NIIMBL member portal to access additional project information, including presentations, progress updates, reports, and more.
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.
Massachusetts Institute of Technology
